Ortin Labs Reports Decline in Q3 Results
Ortin Laboratories, a microcap pharmaceutical company, reported a decline in net sales, standalone net profit, and operating profit (PBDIT) for the quarter ended September 2023. The company's stock has been given a 'Strong Sell' rating by MarketsMojo, with a decrease in operating profit margin and earnings per share.
Ortin Laboratories, a microcap pharmaceutical company, recently declared its financial results for the quarter ended September 2023. The company's stock has been given a 'Strong Sell' rating by MarketsMOJO.
According to the quarterly analysis, there has been a significant decline in net sales, standalone net profit, and operating profit (PBDIT) excluding other income, compared to the previous quarter. The net sales have decreased by -83.44%, while the standalone net profit has seen a decline of -5,700.00%. The operating profit (PBDIT) has also shown a negative growth of -568.42%. However, there has been a slight increase in interest expenses by 36.36%.
The operating profit margin (excluding other income) has also fallen in the quarter ended September 2023, compared to the previous quarter. This has resulted in a decrease in the overall financial performance of Ortin Labs. The company's score has fallen from 1 to -3 in the last three months.
The company's operating profit and profit before tax (PBT) have been at their lowest in the last five quarters, indicating a negative trend in the near term. The earnings per share (EPS) have also decreased, creating lower earnings for shareholders.
Overall, the financial results for the quarter ended September 2023 have not been favorable for Ortin Laboratories. The company will need to address the declining trends and work towards improving its financial performance in the future.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
